CLINICAL_TRIALS trial_result · 2024-06-06

Clinical Trial Update: Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients [Phase 2]

Phase 2 trial assessing the efficacy and safety of VAY736 and CFZ533 in systemic lupus erythematosus has completed with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Novartis Pharmaceuticals | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 2 | Status: COMPLETED | Results posted: 2024-06-06